A Double-Blind, Randomized, Placebo-Controlled, Single-Centre Phase I Pharmacodynamic Cross-Over Study to Assess the Effect of a Single Dose of AZD2066 Oral Solution in Comparison to Placebo on Transient Lower Esophageal Sphincter Relaxations (TLESRs) in Healthy Subjects.

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Single-Centre Phase I Pharmacodynamic Cross-Over Study to Assess the Effect of a Single Dose of AZD2066 Oral Solution in Comparison to Placebo on Transient Lower Esophageal Sphincter Relaxations (TLESRs) in Healthy Subjects.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Apr 2012

At a glance

  • Drugs AZD 2066 (Primary)
  • Indications Gastro-oesophageal reflux; Neuropathic pain
  • Focus Pharmacodynamics
  • Most Recent Events

    • 06 Dec 2010 Trial phase changed from I to I/II as reported by ClinicalTrials.gov.
    • 18 Nov 2009 Actual number of patients (40) added as reported by ClinicalTrials.gov.
    • 18 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top